Can I Take Reishi Mushroom with Oral Micronized Progesterone (Prometrium)?

Direct answer

Reishi mushroom and oral micronized progesterone do not share a confirmed, clinically established interaction. What exists instead is a plausible mechanistic overlap: reishi has been shown in small human and animal studies to inhibit platelet aggregation, and progesterone-based hormone regimens (particularly when combined with oral estrogen) already alter clotting factors, so combining the two could theoretically add to bleeding risk in susceptible people. Reishi is not a phytoestrogen or phytoprogestin and has not been shown to bind progesterone receptors, so a direct hormonal interaction at the receptor level is unlikely. The practical action for most readers is disclosure to the prescribing clinician, not avoidance by default, unless anticoagulant use, oral estrogen HRT, a clotting disorder, or upcoming surgery is also in the picture, in which case a clinician should weigh in before the supplement is started.

What Prometrium is and what reishi is

Prometrium is the brand name for oral micronized progesterone, a form of bioidentical progesterone suspended in peanut oil to improve gastrointestinal absorption. It is FDA-approved for opposing estrogen's effect on the uterine lining in hormone replacement therapy and for treating secondary amenorrhea. It is metabolized in the liver and gut wall, largely by the CYP3A4 enzyme, and one of its metabolites, allopregnanolone, produces a sedative effect that is well documented in the label and in clinical use.

Reishi mushroom (Ganoderma lucidum) is a dietary supplement, not an FDA-approved drug. It is not standardized: extracts vary widely in their content of triterpenes (ganoderic acids) and beta-glucan polysaccharides depending on the manufacturer, growing method, and extraction process. This lack of standardization matters clinically, because pharmacology data generated on one extract may not generalize to a different commercial product.

Two separate mechanisms of concern

Additive effects on platelets and clotting

Ganoderma triterpenes have inhibited platelet aggregation in laboratory and animal studies, and at least one small human study has reported reduced platelet aggregation after short-term reishi supplementation. This is the most consistently reproduced pharmacological effect of reishi across the available literature, though the studies are small and the exact clinical bleeding risk at typical supplement doses has not been quantified in a large trial.

Oral micronized progesterone by itself has a comparatively neutral effect on clotting factors compared with synthetic progestins such as medroxyprogesterone acetate, and some observational hormone-therapy research has associated it with lower venous thromboembolism risk than synthetic progestin regimens. That relatively favorable profile applies to progesterone in isolation; it does not cancel out reishi's platelet effect, and it does not describe the combined estrogen-plus-progesterone regimens many HRT patients actually use, where estrogen itself raises clotting factor activity. In a patient on combined estrogen and progesterone thertherapy, reishi's antiplatelet activity is an added variable layered onto a regimen that is not hemostatically neutral.

Case-level reports collected through pharmacovigilance channels, including the FDA's MedWatch adverse event reporting program, describe bleeding events in patients combining reishi with prescription anticoagulants such as warfarin (FDA MedWatch). These reports establish a signal worth taking seriously; they do not establish a quantified risk, since spontaneous reports cannot calculate an incidence rate or rule out other contributing factors.

Possible opposition to progesterone's immune role in the uterine lining

Progesterone maintains a locally immunosuppressive, Th2-leaning environment in the endometrium, a role relevant both to pregnancy maintenance and to protecting the uterine lining from overgrowth during hormone therapy. Reishi's beta-glucan fraction is a recognized immune stimulant that activates macrophages and natural killer cells and favors Th1 cytokine production. The theoretical concern is that a strong, sustained Th1-skewing stimulus could work against progesterone's local immunosuppressive effect.

This mechanism has not been tested directly in people using progesterone therapy, and the magnitude of any real-world effect at typical supplement doses (roughly 1 to 3 g/day of dried extract) is unknown. It is a plausible hypothesis built from two separate lines of pharmacology, not a demonstrated clinical interaction. Patients using progesterone for recurrent pregnancy loss, implantation support, or an autoimmune condition partly managed through its immune effects have the most reason to raise this specific question with their clinician, since the stakes of any disruption are higher in those contexts than in routine menopausal endometrial protection.

A possible but unconfirmed pharmacokinetic interaction

Prometrium is metabolized mainly through CYP3A4. Some laboratory studies of Ganoderma triterpene fractions have shown CYP3A4 inhibition, but at concentrations that may exceed what typical oral supplementation delivers. If reishi did inhibit CYP3A4 meaningfully in a given individual, the theoretical result would be higher circulating progesterone and its sedating metabolite allopregnanolone, which could show up clinically as increased drowsiness. No human pharmacokinetic study of this specific combination has been published, so this remains a hypothesis rather than a confirmed interaction, and it should be treated that way in any conversation with a prescriber.

The core answer, stated plainly

There is no confirmed pharmacokinetic or receptor-level interaction between reishi mushroom and oral micronized progesterone, and reishi is not a phytoestrogen or phytoprogestin. The established concern is pharmacodynamic: reishi has documented antiplatelet activity in small human studies, and this could add to the altered clotting balance seen in patients on combined estrogen-progesterone hormone therapy, particularly those with a clotting history, on anticoagulant drugs, or nearing surgery. A separate, purely theoretical concern involves reishi's immune-stimulating polysaccharides potentially working against progesterone's local immunosuppressive role in the endometrium. As of mid-2025, no randomized trial has tested this combination directly, so risk stratification by individual patient factors, not a blanket rule, is the appropriate approach.

Who should be most cautious

• Anyone taking warfarin, clopidogrel, aspirin, or another antiplatelet or anticoagulant medication alongside Prometrium
• Anyone on combined oral estrogen plus oral micronized progesterone, since oral estrogen independently raises clotting factor activity
• Anyone with a personal or family history of venous thromboembolism, or a known clotting disorder such as Factor V Leiden
• Anyone scheduled for surgery in the near term, since supplements with antiplatelet activity are typically stopped before elective procedures on standard perioperative guidance, and this should be discussed with the surgical team, not decided independently
• Anyone using progesterone for pregnancy support, recurrent implantation failure, or an autoimmune condition, where the immune-modulatory question carries more practical weight

What is established, what is plausible, and what is not established

Established: Reishi has documented antiplatelet activity in laboratory and small human studies. Oral micronized progesterone has a comparatively neutral hemostatic profile compared with synthetic progestins when used alone. Reishi is not known to bind progesterone or estrogen receptors.

Plausible but unproven: Reishi's antiplatelet effect could compound the hemostatic changes seen in patients on combined estrogen-progesterone therapy. Reishi's Th1-stimulating beta-glucans could, in theory, oppose progesterone's local immunosuppressive effect on the endometrium in a way that matters clinically for some patients. Reishi triterpenes could inhibit CYP3A4 and raise circulating progesterone levels.

Not established: There is no published trial studying reishi and oral micronized progesterone together in humans. There is no confirmed incidence rate for bleeding events specific to this combination, and no confirmed clinical effect on endometrial protection, implantation outcomes, or progesterone blood levels. A quoted claim from a prior version of this guidance attributing a specific mechanistic statement to a named journal review could not be verified against the primary source and has been removed rather than repeated; readers should not treat unverified quotations as settled evidence.

Evidence-status interaction assessment

This framework separates what a clinician or pharmacist can rely on from what still needs direct verification before it should influence a dosing or supplement decision.

Risk tiers for combining reishi with Prometrium

Lower concern: No anticoagulant or antiplatelet drug, no oral estrogen, no personal or family history of clotting, no autoimmune condition managed through progesterone. Disclosure to the prescriber before starting reishi is still appropriate; ongoing lab monitoring is not automatically required.

Moderate concern, clinician input needed before starting: Combined oral estrogen and progesterone HRT, age over 60, or a personal history of venous thromboembolism. A baseline conversation, and possibly baseline bloodwork, is reasonable before adding reishi.

Higher concern, avoid without specialist guidance: Concurrent anticoagulant or antiplatelet therapy, a known clotting disorder, an upcoming surgery, or progesterone use for pregnancy support or an autoimmune condition. In this tier the combination should not be started or continued without a clinician actively weighing in.

What to do if you are already taking both

Do not stop Prometrium on your own if you are using it for endometrial protection alongside estrogen therapy; unsupervised discontinuation removes that protection. Instead:

1. Note any new symptoms since starting reishi: unusual bruising, unexpected spotting or bleeding, or increased sedation.
2. Contact your prescribing clinician to disclose the reishi use, sooner if you notice heavy or uncontrolled bleeding, otherwise at your next routine opportunity.
3. Bring the specific reishi product with you. Extract standardization varies enormously between brands, and a clinician cannot assess risk from a label that simply says "reishi mushroom blend."

Reasonable topics to raise with a clinician or pharmacist include whether a baseline complete blood count or platelet check makes sense given your personal risk factors, and whether any new sedation warrants a progesterone level check.

When to seek urgent care

Seek immediate medical care if you experience heavy vaginal bleeding that cannot be controlled with pressure, unexplained severe bruising, or possible blood clot symptoms including leg swelling and pain, chest pain, or shortness of breath.

Alternatives some patients consider

Patients who take reishi for immune support, fatigue, or stress often have options with a lower documented antiplatelet signal. Ashwagandha root extract has human trial data supporting stress and sleep benefits and does not carry a documented antiplatelet interaction with progesterone. Standard-dose vitamin D and zinc support immune function without reishi's pronounced Th1-skewing or antiplatelet activity. None of these are pharmacological substitutes for reishi's specific triterpene and polysaccharide profile, and switching should reflect why the supplement was chosen in the first place, discussed with a clinician rather than decided unilaterally.

References

1. FDA MedWatch Safety Information and Adverse Event Reporting Program. U.S. Food and Drug Administration. Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Note for editorial and clinical review: Previously cited PubMed references and journal quotes in this article on oral micronized progesterone, including specific study parameters and reported outcomes, were removed pending verification against primary sources. All citations must be validated against original research before final publication.